Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER+ Breast Cancer Patients

Dr. Edith Perez, deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida, discusses new study findings: A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida. Learn more here on this subject: http://newsnetwork.mayoclinic.org/dis...